Year: 2015-16

Company: Thermo Fisher Scientific

Liaison(s): Robert Shaw Craig Smith

Thermo Fisher Scientific Inc. (NYSE: TMO) is the
world leader in serving science, with revenues of
$17 billion and approximately 50,000 employees in
50 countries. The company’s mission is to enable its
customers to make the world healthier, cleaner and
safer. Thermo Fisher helps customers accelerate life
sciences research, solve complex analytical challenges,
improve patient diagnostics and increase laboratory
productivity. Through its premier brands – Thermo
Scientific®, Applied Biosystems®, Invitrogen®,
Fisher Scientific® and Unity Lab Services® – the
company offers an unmatched combination of
innovative technologies, purchasing convenience and
comprehensive support.
The BioProduction division at Thermo Fisher
represents a rapidly growing business unit with a
plethora of new project initiatives in the product
development pipeline. The division seeks short and
long-term solutions for balancing the risk and reward
profile of the portfolio in order to facilitate double-
digit organic revenue growth.
The Thermo Fisher TMP team performed in-depth
research and benchmarked best practices in portfolio
management in order to help create a sustainable
portfolio optimization plan. The team utilized project
portfolio optimization literature and primary research
interviews to construct customized portfolio models
designed specifically for the BioProduction division
business case. In addition, the team performed
an evaluation of commercially available portfolio
management software solutions with advanced
capabilities. Through the deliverables of this project,
the team has provided Thermo Fisher with a suite
of tools that will allow the division to execute their
corporate strategy with a monitored and analytical
approach.